EM
AVEO

Excalibur Management’s AVEO Pharmaceuticals, Inc. AVEO Stock Holding History

Excalibur Management’s Portfolio AVEO Stock Details AVEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-5,100
Closed -$32K – 142
2019
Q4 		$32K Hold
5,100
– – 0.02% 110
2019
Q3 		$43K Hold
5,100
– – 0.04% 65
2019
Q2 		$34K Hold
5,100
– – 0.03% 61
2019
Q1 		$42K Buy
5,100
+4,000
+364% +$41.3K 0.04% 61
2018
Q4 		$18K Hold
1,100
– – 0.02% 59
2018
Q3 		$36K Hold
1,100
– – 0.03% 67
2018
Q2 		$25K Hold
1,100
– – 0.02% 77
2018
Q1 		$32K Hold
1,100
– – 0.03% 77
2017
Q4 		$31K Hold
1,100
– – 0.03% 77
2017
Q3 		$40K Buy
+1,100
New +$34K 0.03% 77

Other funds holding AVEO

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
XSC
X-Square Capital Guaynabo, Puerto Rico $297M AUM 32.87% 1-Year Est. Return
WG
Winton Group London, United Kingdom $2.85B AUM 30.73% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Excalibur Management's AVEO Position: Q1 2020 in Review

Excalibur Management sold out of AVEO Pharmaceuticals, Inc. (AVEO) in Q1 2020, closing a stake of 5,100 shares — an estimated $32K sold.

Excalibur Management first reported a position in AVEO in Q3 2017 and held it in 10 quarters. The position peaked at $43K in Q3 2019. 35 funds tracked by Wall St. Rank hold AVEO as of Q1 2020.

  • Excalibur Management reported no remaining AVEO Pharmaceuticals, Inc. position as of Q1 2020 after selling out during the quarter.
  • Excalibur Management sold 5,100 AVEO Pharmaceuticals, Inc. shares in Q1 2020, an estimated $32K.
  • Excalibur Management first reported a position in AVEO Pharmaceuticals, Inc. in Q3 2017 and held it in 10 quarters.
  • Excalibur Management's AVEO Pharmaceuticals, Inc. position peaked at $43K in Q3 2019.
  • 35 funds tracked by Wall St. Rank held AVEO Pharmaceuticals, Inc. as of Q1 2020.

Based on Excalibur Management's 13F filing for Q1 2020, filed 15 May 2020.